

# Discrimination of Clinical Stages in Lung Cancer Patients by Serum HSP27 and HSP70

Diplomarbeit  
Zimmermann Matthias


ausgeführt an der  
Universitätsklinik für Chirurgie  
Christian Doppler Laboratory for Cardiac and Thoracic Diagnosis and Regeneration

unter der Anleitung von  
Ass.-Prof. Univ.-Doz. Dr. Hendrik Jan Ankersmit


# Background

## Lung Cancer - Epidemiology

- most common cancer in terms of mortality worldwide
- incidence rate: 1.2 million/year
- mortality rate: 1.1 million/year
- 5-year survival: mean 10 – 14%




Rate (%)





Female Breast

Distant Stage


Pro



# Background Screening Programmes



© 2001 U.S. Gc





# Background

## Heat Shock Proteins in COPD

Clin Lab 2009;55(1-2):31-40.

### Elevated HSP27, HSP70 and HSP90 alpha in chronic obstructive pulmonary disease: markers for immune activation and tissue destruction

Hacker S, Lambers C, Hoetzenecker K, Pollreisz A, Aigner C, Lichtenauer M, Mangold A, Niederpold T, Zimmermann M, Taghavi S, Klepetko W, Ankersmit HJ.





# Background Lung Cancer & COPD

Eur Respir J 2010; 35: 146-151  
DOI: 10.1183/09031936.00049909  
Copyright ©ERS Journals Ltd 2010

- smo
- envi
- gene
- airw
- lung
- 40-7

Lung function predicts lung cancer risk in smokers: a tool for targeting screening programmes

E. Calabrò\*, G. Randi<sup>#,†</sup>, C. La Vecchia<sup>#,†</sup>, N. Sverzellati<sup>+</sup>, A. Marchionò<sup>§</sup>, M. Villani<sup>†</sup>, M. Zompatori<sup>\*\*</sup>, R. Cassandro<sup>##</sup>, S. Harari<sup>##</sup> and U. Pastorino\*



Houghton A et al., Nat Med 2008;14:1023-24

# Background

## Heat Shock Proteins

- Induced by different kinds of stress (heat, irradiation, oxidative stress,...)
- classified according to their molecular mass  
(HSP10, HSP27, HSP 40, HSP 60, HSP70, HSP90 and HSP110)
- strong cytoprotective effect
  - molecular chaperones (protein holding and folding)
  - inhibition of key effectors of the apoptotic machinery
  - Participation in proteasome-mediated degradation of proteins under stress conditions
- usually intracellular chaperones
- release after cell stress and trauma → extracellular „danger signal“
- modulation of the immune response

Stress Protein	Intracell
Hsp27	Chape
Hsp60	Chape
Hsp70	Chape
Hsp90	Chape
Hsp110	Ch


# Background

## Heat Shock Proteins

- Properties of the HSPs are co-opted during malignant progression
- HSPs are overexpressed in a wide range of malignant cells and tissues
- increased transcription of HSPs due to loss of p53 function and to higher expression of proto-oncogenes HER2 and c-Myc
- promoting autonomous cell proliferation
- Inhibiting death pathways

# Background

## Heat Shock Proteins in Lung Cancer




Immunohistochemical staining of non-small cell lung carcinomas with antibody to heat shock protein 70. Left: negative tumor; right: positively stained tumor.



# Background


## Heat Shock Proteins in Lung Cancer



Immunohistochemical localization of HSP70i in differentiated squamous cell carcinoma

Evaluation of HSP27 and HSP70 in NSCLC patients and controls

- ➔ elevated HSP27/70 serum levels in NSCLC patients?
- ➔ discrimination between early (IA-IIIB) and advanced (IIIA-IV) stage lung cancer by means of HSPs?



histological verification  
staging according to TNM classification  
early (IA-IIIB) and advanced (IIIA-IV) stage NSCLC  
lung function testing  
acquisition of serum samples



ELISA



SPSS  
GraphPad Prism 5




# Demographics




	healthy		NSCLC		total	P
	non smokers	smokers	early stage	advanced stage		
<b>n</b>	33	24	37	72	166	-
<b>M / F %</b>	48.5 / 51.5	37.5 / 62.5	59.5 / 40.5	56.9 / 43.1	53.0 / 47.0	<i>n.s.</i>
<b>Age (years)</b>	55.8 ± 7.8	56.3 ± 7.0	59.9 ± 6.2	57.8 ± 6.9	57.6 ± 7.1	<i>n.s.</i>
<b>Smoking History %</b>						
<b>Current/Ex</b>	0	100	73.0	63.9	58.4	
<b>Never</b>	100	0	13.5	7.0	25.9	-
<b>No details</b>	0	0	13.5	29.1	15.7	
<b>Lung Function</b>						
<b>FVC(L)</b>	3.73 ± 0.98	3.52 ± 0.85	3.50 ± 0.81	3.18 ± 0.91	3.44 ± 0.93	<i>n.s.</i>
<b>FEV1(L)</b>	2.96 ± 0.73	2.71 ± 0.67	2.46 ± 0.74	2.12 ± 0.75	2.48 ± 0.82	***
<b>FEV1%</b>	99.4 ± 9.5	92.1 ± 13.9	79.2 ± 20.8	71.3 ± 22.5	82.2 ± 21.8	***
<b>FEV1/VC</b>	0.80 ± 0.06	0.77 ± 0.06	0.70 ± 0.11	0.66 ± 0.13	0.72 ± 0.12	***

# Results I



mean	1648	2346	3647	5364
±	±	±	±	±
SD	777	1080	1613	2679




305	321	603	793
±	±	±	±
212	316	386	545


\*\*\* < 0.001

\*\* < 0.01

# Results II



	median pg/ml	IQR pg/ml
IA – IIB	315	172 – 527
IIIA - IV	447	229 – 1733



	AUC	95% CI	P
HSP27	0.870	0.817 – 0.923	<0.0001
HSP70	0.779	0.707 – 0.851	< 0.0001
phospho-HSP27	0.682	0.580 – 0.784	0.0019

# Results III

healthy controls

stage		healthy nonsmokers	healthy smokers
<i>n</i>		33	24
<b>HSP27</b>	median	1482	2242
	IQR	1136–2071	1787–3009
<b>HSP70</b>	median	285	244
	IQR	166–345	82–456

NSCLC early stage

stage		Ia	Ib	IIa	IIb
<i>n</i>		10	15	3	9
<b>HSP27</b>	median	3452	3198	2689	4377
	IQR	1823–4347	2469–4206	2258–4074	3105–5626
<b>HSP70</b>	median	643	517	1014	616
	IQR	129–847	246–806	58–1748	344–791

NSCLC advanced stage

stage		IIIa	IIIb	IV	<i>P</i>
<i>n</i>		16	6	50	
<b>HSP27</b>	median	4023	4339	5558	<0.0001
	IQR	3025–7355	3371–8620	2854–8125	
<b>HSP70</b>	median	452	825	719	<0.0001
	IQR	282–1147	318–1796	432–1105	



# Conclusions

Serum levels of HSP27 and HSP70 are significantly elevated in NSCLC patients compared with healthy controls

HSP27 serum levels show a stage-dependent increase in early and advanced stage NSCLC

HSP27 serum levels show excellent sensitivity and specificity in a regression model (NSCLC vs. healthy)